Utilizza questo identificativo per citare o creare un link a questo documento: http://elea.unisa.it/xmlui/handle/10556/1461
Record completo di tutti i metadati
Campo DCValoreLingua
dc.contributor.authorD'Alessandro, Alba-
dc.date.accessioned2014-07-08T08:22:41Z-
dc.date.available2014-07-08T08:22:41Z-
dc.date.issued2014-03-14-
dc.identifier.urihttp://hdl.handle.net/10556/1461-
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-305-
dc.description2012-2013en_US
dc.description.abstractThe mevalonate pathway is an important metabolic pathway implicated in multiple aspects of tumorigenesis. In this study, I provided evidences about genetic and pharmacologic perturbation of p53, which directly influenced expression of mevalonate pathway enzymes, including 3’-Hydroxy-3’-Methylglutaryl - CoenzymeA Reductase, Mevalonate Kinase, Farnesyl Diphosphate Synthase, Farnesyl Diphosphate Farnesyl Transferase 1. Three different cell lines have been considered, U343 MG (U343) and U251 MG (U251) glioma cells, both classified as IV grade glioblastoma cell lines, with two different malignancy grade, and Normal Human Astrocytes (NHA),their normal counterpart. In particular, NHA and U343 cells have wild type p53 (wtp53) while U251bearing mutation (R273H)p53. This mutation affects p53 DNA binding site, preventing transcriptional function of the protein. Different basal expression level of the mevalonate pathway’s genes have found among the different cell lines considered and I hypothesized that this could be ascribable to p53 mutation status and function. Indeed, I observed that functional and active p53 recognized specific p53 Responsive Elements (p53REs) present in MVA enzymes gene-sequences. p53 bound to these regions correlated with increased transcription levels of mentioned genes and such effect has abolished in cells bearing mut(R273H)p53 or by site-directed mutagenesis of p53REs. These new findings expose another facet of p53 functions, unrelated to tumor suppression, and render it a novel regulator of mevalonate pathway providing insight into the role of this pathway in cancer progression. [edited by author]en_US
dc.language.isoenen_US
dc.publisherUniversita degli studi di Salernoen_US
dc.subjectMevalonate pathwayen_US
dc.subjectp53en_US
dc.subjectCancer developmenten_US
dc.titlep53 regulates Mevalonate Metabolic pathwayen_US
dc.typeDoctoral Thesisen_US
dc.subject.miurMED/04 PATOLOGIA GENERALEen_US
dc.contributor.coordinatoreBifulco, Maurizioen_US
dc.description.cicloXII n.s.en_US
dc.contributor.tutorBifulco, Maurizioen_US
dc.identifier.DipartimentoFarmaciaen_US
È visualizzato nelle collezioni:Fisiopatologia, diagnostica e terapia molecolare delle malattie metaboliche

File in questo documento:
File Descrizione DimensioniFormato 
tesi A. D'Alessandro.pdftesi di dottorato2,75 MBAdobe PDFVisualizza/apri
abstract in inglese A. D'Alessandro.pdfabstract in inglese a cura dell'autore163,04 kBAdobe PDFVisualizza/apri
abstract in italiano A. D'Alessandro.pdfabstract in italiano a cura dell'autore164,25 kBAdobe PDFVisualizza/apri


Tutti i documenti archiviati in DSpace sono protetti da copyright. Tutti i diritti riservati.